title: Autoimmunity in the pathogenesis and treatment of keratoconjunctivitis sicca.
abstract: Dry eye is a chronic corneal disease that impacts the quality of life of many older adults. Keratoconjunctivitis sicca (KCS), a form of aqueous-deficient dry eye, is frequently associated with Sjögren's syndrome and mechanisms of autoimmunity. For KCS and other forms of dry eye, current treatments are limited, with many medications providing only symptomatic relief rather than targeting the pathophysiology of disease. Here, we review proposed mechanisms in the pathogenesis of autoimmune-based KCS: genetic susceptibility and disruptions in antigen recognition, immune response, and immune regulation. By understanding the mechanisms of immune dysfunction through basic science and translational research, potential drug targets can be identified. Finally, we discuss current dry eye therapies as well as promising new treatment options and drug therapy targets.
authors.affiliation: Department of Ophthalmology, University of North Carolina at Chapel Hill School of Medicine, CB# 7040, 5151 Bioinformatics Building, Chapel Hill, NC, 27599, USA, katy_liu@med.unc.edu.
authors.forename: Katy C
authors.initials: KC
authors.lastname: Liu
authors.forename: Kyle
authors.initials: K
authors.lastname: Huynh
authors.forename: Joseph
authors.initials: J
authors.lastname: Grubbs
authors.forename: Richard M
authors.initials: RM
authors.lastname: Davis
mesh_terms: D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D017209:Apoptosis / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology; D015551:Autoimmunity / Q000276:immunology*; D016572:Cyclosporine / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D056724:Immunity, Humoral / Q000276:immunology; D007638:Keratoconjunctivitis Sicca / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*; D018716:Molecular Mimicry; D011812:Quinuclidines / Q000627:therapeutic use; D012859:Sjogren's Syndrome / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D013876:Thiophenes / Q000627:therapeutic use
chemical_list: D001323:Autoantibodies; D011812:Quinuclidines; D013876:Thiophenes; D016572:Cyclosporine; C059240:cevimeline